Overview

A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420)

Status:
COMPLETED

Trial end date:
2023-12-15

Target enrollment:

Participant gender:

Summary

Pain is a significant issue and there is a need for better treatments for pain management. Local changes in skin blood flow can be used as an indicator of pain in the body. Capsaicin and allyl isothiocyanate (AITC) increase blood flow and cause pain. The purpose of this study is to evaluate the use of laser speckle contrast imaging (LSCI) as a tool to assess changes in skin blood flow. Researchers want to learn about the effect size and reproducibility of using LSCI to measure the blood flow response to capsaicin and AITC.

Phase:

PHASE1

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

2,3,4-tri-O-acetylarabinopyranosyl isothiocyanate
allyl isothiocyanate
Capsaicin